Clinical Scorecard: Comparative Analysis of Neoadjuvant Chemotherapy Combined with Immunotherapy Versus Chemotherapy Alone in Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials

At a Glance

Key Highlights

• Neoadjuvant chemoimmunotherapy (NIC) significantly improves major pathological response (MPR) and pathological complete response (pCR) compared to neoadjuvant chemotherapy (NC).
• NIC shows a trend towards improved overall survival (OS) and R0 resection rates.
• Higher incidence of immune-related adverse events (iRAEs) observed with NIC, though severe adverse events were similar between groups.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of esophageal squamous cell carcinoma should be confirmed through histopathological evaluation.

Management

• Consider neoadjuvant chemoimmunotherapy for patients with resectable ESCC to improve pathological response and surgical outcomes.

Monitoring & Follow-up

• Monitor for immune-related adverse events during treatment with NIC.

Risks

• Increased incidence of immune-related adverse events with NIC compared to NC.

Patient & Prescribing Data

Patients diagnosed with resectable esophageal squamous cell carcinoma.

Neoadjuvant chemoimmunotherapy may offer improved pathological responses and surgical rates, but with a higher risk of immune-related adverse events.

Clinical Best Practices

• Integrate immune checkpoint inhibitors into neoadjuvant treatment protocols for ESCC.
• Utilize multiple outcome measures, including MPR and pCR, to assess treatment efficacy.

Related Resources & Content

• Meta-Analysis of RCTs on NIC vs. NC